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ABSTRACT: Radiotherapy and chemotherapy cause genotoxic side effects that are highly variable among patients. 
In this study, we evaluated DNA integrity using the comet assay in peripheral blood lymphocytes from breast cancer 
patients before (“pre-treatment patients”; n = 47) and after (“post-treatment patients”; n = 24) radiotherapy and/or 
chemotherapy treatment and from healthy donors (n = 15). Comet evaluation was made by visual (types 0–4) and 
digital (percentage of DNA remaining in the comet head = % head DNA) analysis. The association between the level 
of DNA damage and cancer prognostic factors was assessed. The treatments caused a significant increase in DNA 
damage registered by both visual (p < 0.001) and digital (p < 0.001) analyses. No significant associations between 
the level of DNA damage in pre-treatment patients and cancer prognostic factors were found. A significant correla-
tion between the comet results from each patient before and after treatment (r = 0.64, p = 0.001) was observed. The 
% head DNA in post-treatment samples from patients with a high level  of DNA damage before treatment (30.3 ± 
3.1%, p < 0.01) was lower than in post-treatment samples from patients with a low-to-medium level of DNA dam-
age before therapy (49.2 ± 4.4%). These results support the usefulness of the comet assay as a sensitive technique 
to evaluate basal DNA status and DNA damage caused by cancer treatments. The comet assay could contribute to 
treatment decisions, especially by taking into account the patient’s basal DNA damage before therapy.
KEY WORDS: comet assay, genotoxic damage, peripheral blood lymphocytes, prognostic factors 
I. INTRODUCTION
Exposure to genotoxic agents during chemotherapy or 
radiotherapy can produce a wide variety of side effects 
in human health.1 The efficiency of radiotherapy is 
limited by the adverse side effects in normal tissues 
when exposed to radiation. Generally, more than 
5% of breast cancer patients develop acute or late 
symptoms of enhanced radiosensitivity.2 Acute 
side effects, such as erythema and desquamation 
of the exposed skin and mucosa, occur during 
or shortly after therapy, whereas depending on 
elapsed time, late effects can vary from severe 
tissue alterations (e.g.,  fibrosis and telangiec-
tasia) to secondary malignancies.3 Furthermore, 
after therapeutic exposure to ionizing radiation, 
different levels of damages can be identified at 
the nuclear DNA level.2
In addition to the beneficial actions of che-
motherapy, the adverse consequences of its action 
on normal tissues are observed very frequently. 
Anti-tumor drugs generally do not selectively affect 
tumor-cell DNA.4 Indeed, following in vivo exposure 
to antineoplastic drugs, diverse lesions in DNA are 
induced.5 In fact, several studies have shown that 
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patients with a successful response to chemotherapy 
have a higher risk of developing secondary cancers.6
Decisions regarding the use of adjuvant ther-
apy are strongly influenced by the risk of disease 
recurrence and death. These risks are assessed by 
examining prognostic factors of breast cancer, such as 
axillary lymph-node metastasis, age, and some tumor 
characteristics (e.g., size, histologic and nuclear 
grades, and estrogen and progesterone receptor sta-
tus). Regarding these factors, the presence of node 
metastasis, lower age at clinical detection, larger 
tumor size, higher histologic and nuclear grades, 
and absence of hormone receptors are markers of 
poor prognosis.7
DNA damage caused by anti-neoplastic drugs 
and ionizing radiation includes nucleotide dam-
age, breaking of hydrogen bonds between the two 
helices, single-strand breaks, double-strand breaks, 
appearance of apurinic or apyrimidinic sites, DNA 
protein cross-links, DNA–DNA interstrand cross-
links, DNA intrastrand cross-links, and generation 
of reactive oxygen species, which, in turn, cause 
more DNA damage.2,8,9
DNA damage related to the exposure of cancer 
patients to therapy is frequently determined using 
peripheral blood lymphocytes as target cells. Lym-
phocytes have been proven to be good surrogate cells 
with which to investigate DNA damage because they 
are affected by agents used in cancer treatment and 
also are easy to obtain.8,10
Diverse methodological approaches have been 
developed to assess the genotoxic damage. Among 
them, the comet assay (single-cell gel electrophoresis) 
is a simple method for measuring DNA integrity in 
individual cells. The alkaline version of the assay 
allows to detect DNA single- and double-strand 
breaks, alkali-labile sites (e.g., apurinic and apy-
rimidinic sites), DNA–DNA and DNA–protein 
cross-linking, and single-strand breaks associated 
with incomplete excision repair sites.11,12 In recent 
years, the comet assay has become an important tool 
in genetic toxicology.10,13
Different studies have indicated that some cancer 
treatments cause highly variable DNA damage among 
patients, even when the same therapy is applied. This 
could be partially explained by the fact that different 
patients exhibit variable DNA repair capacities.14–16 
Therefore, the effect of cancer therapy on DNA 
integrity depends on individual characteristics. In 
the present study, we aimed to investigate DNA 
damage in peripheral blood lymphocytes from breast 
cancer patients before and after therapy. In addition, 
we wanted to evaluate whether the genotoxic dam-
age caused by treatments was related to the basal 
DNA integrity of each patient. Basal DNA damage 
in patient samples was compared with the values 
obtained from blood samples of normal donors. 
Finally, the possible correlation between basal DNA 
damage and prognostic factors of breast cancer was 
assessed. 
II. MATERIALS AND METHODS
A. Chemicals and Reagents
Unless mentioned in the text, all chemicals and 
reagents were purchased from Sigma-Aldrich (St. 
Louis, MO) or from MP Biomedicals (Santa Ana, 
CA), and they were of the highest purity available.
B. Patients and Donor Samples
The present study was approved by the Centenario 
Hospital Bioethics Committee (Rosario, Argentina). 
Blood samples were obtained intravenously and 
collected in tubes with heparin. Forty-seven breast 
cancer patients (without family history of breast 
cancer), from the Mastology Services of the Cen-
tenario Hospital and the Provincial Hospital from 
Rosario (Argentina), and 15 healthy donors (clinically 
evaluated at Mastology Services) participated in the 
study. The samples obtained from the cancer patients 
before tumor surgery and without any treatment; 
these were considered “pre-treatment” samples. In 
addition, blood samples were obtained from 24 of the 
recruited patients at 60 ± 15 days after they finished 
the first cycle of treatment (chemotherapy and/or 
radiotherapy) following tumor surgery; these were 
considered “post-treatment” samples. Both patients 
and healthy donors signed an informed consent 
allowing the use of their samples.
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C. Separation of Lymphocytes 
Lymphocytes were separated by Percoll (Fluka, 
Steinheim, Germany) density gradients. Briefly, 
3.5 ml blood samples were diluted with 0.9% w/v 
NaCl (Merck, Darmstadt, Germany) and loaded on 
tubes containing 3 ml of 70% Percoll (density: 1.090 
g/ml) and 3 ml of 60% Percoll (density: 1.075 g/ml) 
and centrifuged for 20 min at 350 × g. Cells were 
collected from the Percoll-blood interphase by aspi-
ration with a Pasteur pipette and washed twice with 
phosphate-buffered saline (PBS; HyClone, Logan, 
UT) for 10 min at 200 × g. The pellet was then 
resuspended in PBS. Cells were counted in a hemo-
cytometer chamber, and finally, the concentration 
was adjusted to 7000 cells per 10 µL. Cell viability 
was examined using the trypan blue (Mallinckrodt, 
St. Louis, MO) staining exclusion method.
D. Comet Assay
The comet assay was performed under alkaline 
conditions according to procedures published else-
where.17,18 The assay was carried out in blood lympho-
cytes from healthy donors and breast cancer patients 
immediately after the separation of lymphocytes. 
A total of three replicate microscope slides 
were used for each sample. Slides were dipped 
in a 1% agarose solution (BioRad, Hercules, CA) 
dissolved in distilled water, and air dried overnight 
at room temperature. Ten microliters of lymphocyte 
suspension (7000 cells/10 μL) in PBS was then 
mixed with 90 ml of 0.5% w/v low-melt agarose 
solution (Promega, Madison, WI) in PBS, layered 
onto slides, and allowed to solidify at 4°C. Finally, 
a layer of 0.5% w/v low-melt agarose solution was 
added onto the slides, covered with coverslips, and 
allowed to solidify at 4°C for at least 1 h. After 
removal of the coverslips, slides were immersed in 
lysis buffer containing 2.5 mol/l NaCl, 100 mmol/l 
EDTA (Bio-Rad), 1% v/v Triton X-100 (Promega), 
10% v/v DMSO (Riedel de Haën, Seelze, Germany) 
and 10 mmol/l Tris (Promega), pH 10 for 90 min 
at 4°C. Slides were then immersed in a horizontal 
electrophoresis tank filled with alkaline buffer [300 
mmol/l NaOH (Cicarelli, Santa Fe, Argentina) and 
1 mmol/l EDTA, pH > 13] for 20 min. Afterward, 
electrophoresis was carried out at 4°C for 20 min 
at 20 V. Slides were then washed three times with 
0.4 mol/l Tris-HCl (Sigma-Aldrich, St. Louis, MO; 
pH = 7.5), at 4°C for 5 min. After rinsing, slides 
were fixed with cold ethanol (Merck, Buenos Aires, 
Argentina) for 10 min, washed with distilled water, 
and air dried overnight. The slides were stained 
with 20 µg ml-1 ethidium bromide solution (ICN 
Biomedicals, Aurora, OH), covered with cover-
slips, and examined at 400× magnification in an 
epifluorescence microscope (Olympus, Japan) 
equipped with a digital camera (Olympus D-580). 
At least 50 randomly selected cells were analyzed 
for each replicate slide (n = 3) as described below. 
The evaluation of DNA damage was made either by 
visual or digital scoring.
E. Visual Scoring
Visual scoring is a subjective method based in visual 
classification according to the morphological aspect 
of the comet assay. Comets were classified in five 
different types (representing increasing amounts of 
DNA damage), which is a rapid and simple method 
of analysis with good resolution.19–21 Types were 
considered according to tail extent and intensity and 
head aspect: type 0 (all DNA in the head and no tail: 
without DNA damage), 1, 2, 3, and 4 (almost all 
DNA in tail: severely damaged DNA) (Fig. 1). At 
least 150 comets per sample were classified, and the 
percentage was calculated for each comet type in the 
sample. A score for each sample was calculated as 
the sum of each comet type, previously multiplied 
by its percentage. Therefore, the score (arbitrary 
units) ranged between 0 (100% type 0) and 400 
(100% type 4).20
F. Digital Analysis 
The CASP program was used for the image analysis 
of comets.22 Digital analysis programs allowed us 
to obtain different parameters of comets, such as 
tail length, percentage of tail DNA, percentage of 
head DNA, and tail moment (product of tail length 
and percentage of tail DNA), among others.20 The 
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percentages of tail or head DNA are probably the 
most useful parameters for comparison of results 
within or between laboratories because they give an 
immediate, unambiguous, and objective indication 
of the appearance of comets and are related to the 
DNA break frequency over a wide range of levels 
of DNA damage.20,23 At least 150 comets from each 
sample were analyzed, and the average percentage of 
DNA remaining in the comet head (% head DNA) 
was registered.
G. Tumor Characteristics  
Data regarding tumor histology, size, nuclear 
grade, and detection of lymph-node metastases 
were obtained from the original pathology reports. 
Tumors had been diagnosed by senior pathologists 
using standard criteria for histology and graded 
using the Scarff–Bloom–Richardson criteria.24 The 
immunostaining for estrogen (ER) and progesterone 
(PR) receptors was performed in fixed sections from 
tumor tissue using a standard three-layered strepta-
vidin–avidin–biotin horseradish peroxidase method 
with a mouse anti-human ER primary antibody (1:100 
dilution; M7047, DAKO, Ely, Cambridgeshire, UK) 
or anti-PR antibody 636 (1:100 dilution; M3569, 
DAKO), respectively, and a biotinylated rabbit 
anti-mouse secondary antibody (1:350 dilution; 
E354, DAKO). ER or PR expression was classified 
positive when staining was observed in more than 
10% of cancer cell nuclei. The absence of staining 
was considered a negative result.25 
H. Statistical analysis
The correlation analysis between the average % head 
DNA and prognostic factors, such as the presence 
of lymph-node metastasis, age of patients, tumor 
size, and presence of hormone receptors, was carried 
out by means of contingency tables with proofs 
based on the Fisher’s exact test, using the program 
GRAPH-PAD INSTAT (GraphPad Software, San 
Diego, CA). 
The Student’s t test was used for the statistical 
comparison between mean values of two different 
groups. A linear regression analysis between the 
visual score and the average % head DNA was 
determined, and between % head DNA before and 
after treatment for each patient. In addition, the 
Pearson’s correlation (r) coefficient was calculated 
in both cases. A p < 0.05 was considered statistically 
significant. Results were expressed as media ± SEM.
FIG. 1: Visual scoring of DNA damage from 0 to 4 
according to appearance of comets. Fluorescence 
micrographs of comets stained with ethidium bromide 
and observed in an epifluorescence microscope 
(400×). (A) Type 0 (absence of DNA damage - comet 
without tail). (B, C, D) Type 1 (little DNA damage - 
comet with small tail and big head). (E, F, G) Type 2 
(moderate DNA damage - comet with weak tail and 
big head). (H, I, J) Type 3 (extensive DNA damage 
- comet with big tail and small head). (K) Type 4 
(completely damaged DNA - comet with very small 
or absent head).
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III.  RESULTS 
A. Patient Characteristics
The average age was 57.1 ± 1.5 years (range, 29–80 
years) for patients and 48.2 ± 3.3 years (range, 24–66 
years) for healthy donors. Table 1 shows tumor 
characteristics from the patients participating in this 
study. The sum of some of the analyzed parameters 
differed from the total number of patients because 
some parameters could not be determined in all 47 
patients due to technical problems. Estrogen and 
progesterone receptors could not be assessed in 7 
tumor samples, and histologic and nuclear grades 
were analyzed only in 22 and 30 tumor samples, 
respectively.
B. Comet Analysis 
Cell viability was always higher than 90% for all 
the lymphocyte samples tested using the comet assay 
(data not shown). Comets were visually classified 
under 5 types as indicated in materials and methods 
(section II.E). Figure 1 shows representative images 
obtained for each comet type. The average percentage 
of each comet type did not differ between pre-treat-
ment patients and donors (Fig. 2). Furthermore, 
there was no difference in the average percentage 
of each comet type between healthy donors and 
patients before the treatment (34.6 ± 4.9% vs. 40.7 
± 3.1%, respectively) when only comet types (3 + 4) 
TABLE 1: Clinical features of the tumors
Characteristic n %
Node metastases
Negative 26 55.3
Positive 21 44.7
Tumor size, cm
≤2 28 59.5
>2 19 40.5
Histologic grade
1, 2 18 81.8
3 4 18.2
Nuclear grade
1, 2 23 76.7
3 7 23.3
Estrogen receptors
Positive 31 77.5
Negative 9 22.5
Progesterone receptors
Positive 21 52.5
Negative 19 47.5
Some parameters could not be determined in all the 
tumors. n and %: number and percentage of tumors with 
the indicated characteristic.
FIG. 2: Distribution of comet types (visual analysis). 
(A) Distribution of each comet type in lymphocyte 
samples from donors, pre-treatment patients and 
post-treatment patients groups. (B) Distribution of 
comet types (3 + 4) in donors (n = 15) and pre-treat-
ment patients (n = 47) groups. (C) Distribution of 
comet types (3 + 4) from patients (n = 24) with the 
comet assay performed before and after treatment. 
*** p < 0.001.
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were considered (Fig. 2B). The percentage of comet 
types (3 + 4) significantly increased in lymphocytes 
from patients after receiving chemo/radiotherapy, 
when compared with those found in their respective 
pre-treatment samples (64.3 ± 4.6% vs. 38.3 ± 3.5%, 
p < 0.001; Fig. 2C). 
The visual scores corresponding to normal 
controls and breast cancer patients before therapy 
were similar (Fig. 3A). In the same way, scores from 
post-treatment patients were also significantly higher 
than the pre-treatment scores (p < 0.001; Fig. 3B). 
It is important to note that in every post-treatment 
sample the score always increased respect to their 
value before treatment (Fig. 4). 
The parameter chosen for comparative purposes 
of the digital analysis of comets using the CASP 
program was the average % head DNA. In agreement 
with results of visual analysis, there were no differ-
ences between the values of the % head DNA for 
samples of healthy donors and pre-treatment patients 
(64.0 ± 3.7% vs. 59.7 ± 2.3%, respectively, Fig. 5A). 
As expected, the % head DNA from post-treatment 
samples was significantly lower than the pre-treat-
ment value (38.9 ± 3.2% vs. 62.0 ± 2.6%, respectively, 
p < 0.001, Fig. 5B), indicating a marked increase in 
DNA damage. Data obtained from different groups 
using visual or digital parameters of DNA damage, 
were similar. A correlation analysis between comet 
results from patients before and after treatment 
indicated an extremely significant correlation (r = 
0.64, p = 0.001).
A value of 65% for % head DNA was chosen 
and used to classify the level of DNA damage in the 
pre-treatment samples as low-to-medium (% head 
DNA ≥ 65%) or high (% head DNA < 65%).  Sam-
ples were grouped according to this classification to 
analyze the association of the level of DNA damage 
in pre-treatment patients with age (< 50 years or ≥ 
50 years), the presence of lymph-node metastases, 
the tumor size (< 2 cm or ≥ 2 cm), the histological 
grade (1–2 or 3), the nuclear grade (1–2 or 3), and 
the presence or absence of steroid receptors. As 
shown in Table 2, no significant associations were 
found between the level of DNA damage and these 
characteristics. 
Results from cancer patients (with the comet 
assay performed before and after treatment) were 
divided according to their pre-treatment level of 
DNA damage (low-to-medium or high). The aver-
age % head DNA values after treatment from each 
group were then compared. In patients with a high 
level of DNA damage before therapy, the average % 
head DNA after treatment was 30.3 ± 3.1% and was 
significantly lower than the value from post-treatment 
samples of patients who presented a low-to-medium 
level of DNA damage previous to treatment (49.2 ± 
4.4%; p < 0.01; Table 3). 
FIG. 3: Score distribution (visual analysis).  (A) Score 
distribution in samples from healthy donors (donors) 
and pre-treatment cancer patients (pre). (B) Score 
distribution in samples from breast cancer patients 
with the comet assay assessed before (pre) and after 
(post) the cycle of therapy. *** p < 0.001.
FIG. 4: Scores for the patients before and after 
treatment. Scores for the samples from the 24 breast 
cancer patients subjected to the comet assay before 
(pre-treatment) and after (post-treatment) the first 
cycle of therapy. 
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C. Visual versus Digital Analysis
The results of both methods used for assessing com-
ets were analyzed by linear regression. Statistically 
significant correlations between the results of both 
methods were obtained for the samples of healthy 
donors (r = 0.9525, p < 0.001), cancer patients with-
out treatment (r = 0.9847, p < 0.001), and cancer 
patients after therapy (r = 0.9333, p < 0.001). The 
results indicate that these types of analysis are equally 
useful in assessing DNA damage. 
IV. DISCUSSION
Better therapies have made major contributions to 
improving survival in cancer, but they have meant 
exposure of patients to very high doses of ionizing 
radiation and combinations of high-dose chemother-
apy.1 The risk-benefit equation for a cancer patient 
often determines the appropriate use of treatment 
despite acknowledged side effects.4 In addition, the 
difference between the amount of drug needed to 
induce successful tumoricidal action and the amount 
needed to induce toxicity in the host is small and 
depends on individual characteristics.8 Because 
radiation and most of the drugs applied in breast 
FIG. 5: Distribution of the average percentage of 
DNA remaining in the comet head (% head DNA; 
digital analysis). (A) Values of the average % of head 
DNA in the samples from healthy donors (donors) 
and pre-treatment patients (pre). (B) Values of the 
average % of head DNA in the samples from the 
24 patients obtained before (pre) and after (post) 
treatment. *** p < 0.001.
Characteristic n % head DNA p
≥ 65 % < 65 %
Node 
metastases
44 1.000
Negative 9 14
Positive 9 12
Age, yr 47 0.122
≤50 10 7
>50 10 20
Tumor size, 
cm
43 0.2194
>2 5 12
≤2 13 13
Histologic 
grade
22 0.1150
1, 2 9 9
3 0 4
Nuclear grade 30 1.0000
1, 2 8 15
3 2 5
Estrogen 
receptors
40 0.7053
Positive 13 18
Negative 5 4
Progesterone 
receptors
40 0.3375
Positive 7 14
Negative 10 9
n: number of data known for the indicated characteristic. 
≥65 % or <65 %: number of samples from pre-treatment 
patients with low-to-medium or high level of DNA damage 
(% head DNA ≥65 % or <65 %, respectively). 
TABLE 2: Association between DNA damage in 
the pre-treatment patient’s samples and tumor 
characteristics
cancer treatment affect DNA, DNA damage must be 
considered as a plausible therapy side effect.15 It has 
been reported that the comet assay, using peripheral 
blood lymphocytes, is sensitive enough to detect DNA 
damage as a result of the cancer treatments because 
lymphocytes are also affected by the treatments.14,26 
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It has been suggested that DNA structure in nor-
mal cells from cancer patients is more altered than 
in cells from healthy individuals.11 In this regard, some 
studies have reported that DNA of peripheral blood 
lymphocytes from sporadic breast cancer patients was 
more damaged than that from healthy donors.15,27–29 In 
contrast, other researchers have not found significant 
differences between the basal damage in lymphocytes 
from patients with sporadic breast carcinoma and 
healthy donors.30–33 In the present study, the comet 
assay results of  samples from healthy donors and 
pre-treatment cancer patients were not significantly 
different, either. 
Additionally, it has been proposed that many 
factors such as age, gender, alcohol consumption, 
excessive exercise and diet, among others, could 
affect the result of comet assay; however, in most 
studies, the lack of impact of these factors on the 
results has been reported.9,34 DNA damage may also 
increase with age due to an increased frequency of 
mutations, resulting in accumulation of damaged and 
unrepaired DNA and a reduced DNA repair capacity, 
but many reports do not support this assumption.9,10 
In several studies, the authors did not find an asso-
ciation between age and DNA damage when using 
the comet assay.5,28,29,35,36 In the present study, no 
association between levels of DNA damage and age 
(> 50 years or ≤ 50 years) was found. 
In addition, the results of the present study 
showed no significant associations in levels of DNA 
damage with the presence of lymph-node metastases, 
the tumor size, the histological grade, the nuclear 
grade, and the presence of steroid receptors in 
pre-treatment cancer patients. 
DNA integrity of peripheral blood lymphocytes 
in breast carcinoma patients after therapy was also 
evaluated. A significant increase in DNA damage 
was observed in all post-treatment samples when 
compared to pre-treatment samples. This finding is 
in agreement with previous reports,5,15,27,37 which 
have indicated that the administration of antineo-
plastic drugs and radiotherapy are accompanied by 
significant DNA damage to nucleated blood cells. 
The previous data and the present results support 
the usefulness of the comet assay as a sensitive 
technique to evaluate damage caused by radiotherapy 
or chemotherapy. 
The results of this study reveal a significant cor-
relation between the DNA integrity before and after 
cancer treatment. Cancer patients with high DNA 
damage before treatment showed significantly lower 
values of % of head DNA after therapy than patients 
with low-to-medium DNA damage pre-treatment. 
Thus, it can be inferred that DNA damage caused by 
cancer treatments is associated with the basal DNA 
integrity of each patient. Based on this idea, basal 
DNA integrity of a patient’s lymphocytes could be 
assessed before anticancer therapy to help avoid an 
excessive collateral damage associated with treat-
ment. Therefore, the comet assay could contribute to 
the treatment decisions by considering the patient’s 
basal DNA damage before initiating therapy. 
On the other hand, and in agreement with pre-
vious data,38,39 visual and digital analysis revealed 
TABLE 3: Comparison of the average % head DNA after treatment according to the cancer patient’s 
pre-treatment level of DNA damage 
Sample % head DNA (mean ± SEM)
≥ 65 % (n = 11) < 65 % (n = 13)
Pre-treatment (n =24)a 72.3 ± 2.1 53.4 ± 2.7
Post-treatment 49.2 ± 4.4 30.3 ± 3.1 bp = 0.002
Pre-treatment cancer patients were divided into two groups according to the level of DNA damage. Results are 
expressed as means ± standard error of the mean (SEM), n: number of patients within each subgroup.
aOnly patients with the comet assay performed before and after treatment. bThe mean post-treatment values of % 
head DNA from each group were significantly different (p < 0.01). 
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highly significant correlations for all sample values 
and showed to be equally useful to compare the level 
of DNA damage between different groups. However, 
the visual method can be influenced by the observer 
experience; thus, it is more subjective.40,41 Although 
image analysis provides more objective information, 
Duez et al. reported 4% variability among operators.42 
Thus, and as in most analytical techniques, it is 
important to maintain the same operator throughout 
the study to avoid these variations. 
In conclusion, the efficiency of anticancer ther-
apy is limited by the associated adverse side effects 
having an impact on normal tissues, including several 
non-malignant conditions and a potential risk for 
developing secondary malignant neoplasms. In addi-
tion, the magnitude of side effects is different in each 
patient despite receiving the same treatment. Thus, 
different approaches for evaluating individual risk 
before treatment could be very helpful in diminishing 
the side effects of therapy. One approach could be to 
assess basal DNA integrity in peripheral lymphocytes 
in each patient before therapy using the comet assay. 
Compared to other tests for genotoxic damage, the 
principal advantages of the comet assay include its 
demonstrated sensitivity for detecting DNA damage 
at a very low degree, the requirement for a small 
number of cells per sample, its flexibility, low cost, 
and the relatively short time needed to complete a 
study.43–45
The data collected in the present study suggest 
that the comet assay could contribute to treatment 
decisions by considering the patient’s basal DNA 
damage before therapy. At present, therapy deci-
sions are largely based on prognostic factors, such 
as the presence of node metastases, among others. 
However, treatment side effects vary among patients 
and are hard to predict. Therefore, adding the comet 
assay to regimen of clinical exams carried out before 
treatment could contribute to determining the best 
possible course of treatment for each patient, in a 
complementary way to the prognostic factors, to 
avoid the risk of excessive DNA damage caused by 
treatments. Therefore, side effects from therapy could 
be reduced, and patients could benefit. Using the 
comet assay to inform treatment decisions, patients 
with low basal DNA integrity could receive less 
aggressive treatments, could avoid the combination 
of chemotherapy and radiotherapy, or could receive 
reduced doses or frequency of these therapies. How-
ever,  these approaches remain to be investigated. 
ACKNOWLEDGMENTS
The authors thank Dr. Analia Nocito for her col-
laboration in the anatomical-pathological studies of 
tumor tissues and Dr. Ariel D. Quiroga for careful 
language revision. This study was partially supported 
by grants from SECyT UNR (PID MED132) and 
Florencio Fiorini Foundation from Argentina.
REFERENCES  
1. Byrne J. Long-term genetic and reproductive effects of 
ionizing radiation and chemotherapeutic agents on cancer 
patients and their offspring, Teratology. 1999;59:210–5. 
2. Popanda O, Ebbeler R, Twardella D, Helmbold I, Gotzes 
F, Schmezer P, Thielmann HW, von Fournier D, Haase 
W, Sautter-Bihl ML, Wenz F, Bartsch H, Chang-Claude 
J. Radiation-induced DNA damage and repair in lympho-
cytes from breast cancer patients and their correlation 
with acute skin reactions to radiotherapy. Int J Radiat 
Oncol Biol Phys. 2003;55:1216–25. 
3. Twardella D, Popanda O, Helmbold I, Ebbeler R, Benner 
A, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, 
Schmezer P, Chang-Claude J. Personal characteristics, 
therapy modalities and individual DNA repair capacity as 
predictive factors of acute skin toxicity in an unselected 
cohort of breast cancer patients receiving radiotherapy. 
Radiother Oncol. 2003;69:145–53. 
4. Connor TH, McDiarmid MA. Preventing occupational 
exposures to antineoplastic drugs in health care settings. 
Cancer J Clin. 2006;56:354–65. 
5. Kopjar N, Milas I, Garaj-Vrhovac V, Gamulin M. 
Alkaline comet assay study with breast cancer patients: 
evaluation of baseline and chemotherapy-induced DNA 
damage in non-target cells. Clin Exp Med. 2006;6: 
177–90.
6. Bernard-Marty C, Mano M, Paesmans M, Accettura C, 
Munoz-Bermeo R, Richard T, Kleiber K, Cardoso F, 
Lobelle JP, Larsimont D, Piccart MJ, Di Leo A. Second 
malignancies following adjuvant chemotherapy: 6-year 
results from a Belgian randomized study comparing 
cyclophosphamide, methotrexate and 5-fluorouracil 
(CMF) with an anthracycline-based regimen in adjuvant 
treatment of node-positive breast cancer patients. Ann 
Oncol. 2003;14:693–8. 
Au
ho
r P
of
Journal of Environmental Pathology, Toxicology and Oncology10
Ceballos et al.
7. Corben AD. Pathology of invasive breast disease. Surg 
Clin North Am. 2013;93:363–92.
8. Kopjar N, Garaj-Vrhovac V, Milas I. Assessment of 
chemotherapy-induced DNA damage in peripheral blood 
leukocytes of cancer patients using the alkaline comet 
assay. Teratog Carcinog Mutagen. 2002;22:13–30.
9. Maluf SW. Monitoring DNA damage following radiation 
exposure using cytokinesis-block micronucleus method 
and alkaline single-cell gel electrophoresis. Clin Chim 
Acta. 2004;347:15–24. 
10. Faust F, Kassie F, Knasmüller S, Boedecker RH, Mann 
M, Mersch-Sundermann V. The use of the alkaline comet 
assay with lymphocytes in human biomonitoring studies. 
Mutat Res. 2004;566:209–29. 
11. Rojas E, Lopez MC, Valverde M. Single cell gel elec-
trophoresis assay: methodology and applications. J 
Chromatogr B Biomed Sci Appl. 1999;722:225–54.
12. Singh NP. Microgels for estimation of DNA strand 
breaks, DNA protein crosslinks and apoptosis. Mutat 
Res. 2000;455:111–27.
13. Valverde M, Rojas E. Environmental and occupational 
biomonitoring using the comet assay. Mutat Res. 
2009;681:93–109. 
14. Vaghef H, Nygren P, Edling C, Bergh J, Hellman B. 
Alkaline single-cell gel electrophoresis and human bio-
monitoring for genotoxicity: a pilot study on breast cancer 
patients undergoing chemotherapy including cyclophos-
phamide. Mutat Res. 1997;395:127–38. 
15. Blasiak J, Arabski M, Krupa R, Wozniak K, Rykala J, 
Kolacinska A, Morawiec Z, Drzewoski J, Zadrozny M. 
Basal, oxidative and alkylative DNA damage, DNA repair 
efficacy and mutagen sensitivity in breast cancer. Mutat 
Res. 2004;554:139–48. 
16. Olive PL. Impact of the comet assay in radiobiology. 
Mutat Res. 2009;681:13–23.
17. Singh NP, McCoy MT, Tice RR, Schneider EL. A simple 
technique for quantitation of low levels of DNA damage 
in individual cells. Exp Cell Res. 1988;175:184–91. 
18. Tice R, Vasquez M. Protocol for the application of the pH 
>13 alkaline single cell gel (SCG) assay to the detection of 
DNA damage in mammalian cells, Comet Assay Interest 
Group. 1999. Available from: http://www.cometassay.com.
19. Anderson D, Yu T-W, Phillips BJ, Schmezer P. The effect 
of various antioxidants and other modifying agents on 
oxygen-radical-generated DNA damage in human lym-
phocytes in the COMET assay. Mutat Res. 1994;307: 
261–71. 
20. Collins AR. The comet assay for DNA damage and repair: 
principles, applications, and limitations. Mol Biotechnol. 
2004;26:249–61. 
21. Møller P. Assessment of reference values for DNA damage 
detected by the comet assay in human blood cell DNA. 
Mutat Res. 2006;612:84–104.
22. Końca K, Lankoff A, Banasik A, Lisowska H, Kuszewski 
T, Góźdź S, Koza Z, Wojcik A. A cross-platform public 
domain PC image-analysis program for the comet assay. 
Mutat Res. 2003;534:15–20. 
23. Kumaravel TS, Jha AN. Reliable Comet assay mea-
surements for detecting DNA damage induced by 
ionising radiation and chemicals. Mutat Res. 2006;605: 
7–16.
24. Robbins P, Pinder S, de Klerk N, Dawkins H, Harvey 
J, Sterrett G, Ellis I, Elston C. Histological grading of 
breast carcinomas: a study of interobserver agreement. 
Hum Pathol. 1995;26:873–9.
25. Williams SL, Birdsong GG, Cohen C, Siddiqui M. 
Immunohistochemical detection of estrogen and progester-
one receptor and HER2 expression in breast carcinomas: 
comparison of cell block and tissue block preparations. 
Int J Clin Exp Pathol. 2009;2:476–80.
26. McKenna DJ, McKeown SR, McKelvey-Martin VJ. 
Potential use of the comet assay in the clinical manage-
ment of cancer. Mutagenesis. 2008;23:183–90.
27. Sánchez-Suárez P, Ostrosky-Wegman P, Gallegos-
Hernández F, Peñarroja-Flores R, Toledo-García J, Bravo 
JL, Del Castillo ER, Benítez-Bribiesca L. DNA damage 
in peripheral blood lymphocytes in patients during 
combined chemotherapy for breast cancer. Mutat Res. 
2008;640:8–15.
28. Santos RA, Teixeira AC, Mayorano MB, Carrara HH, 
Andrade JM, Takahashi CS. Basal levels of DNA damage 
detected by micronuclei and comet assays in untreated 
breast cancer patients and healthy women. Clin Exp Med. 
2010;10:87–92. 
29. Smith TR, Miller MS, Lohman KK, Case LD, Hu JJ. 
DNA damage and breast cancer risk. Carcinogenesis. 
2003;24:883–9.
30. Alapetite C, Thirion P, de la Rochefordière A, Cosset 
J-M, Moustacchi E. Analysis by alkaline comet assay 
of cancer patients with severe reactions to radiotherapy: 
defective rejoining of radioinduced DNA strand breaks 
in lymphocytes of breast cancer patients. Int J Cancer. 
1999;83:83–90. 
31. Jianlin L, Jiliang H, Lifen J, Wei Z, Baohong W, Hongping 
D. Measuring the genetic damage in cancer patients during 
radiotherapy with three genetic end-points. Mutagenesis. 
2004;19:457–64. 
32. Djuzenova CS, Mühl B, Fehn M, Oppitz U, Müller B, 
Flentje M. Radiosensitivity in breast cancer assessed 
by the comet and micronucleus assays. Br J Cancer. 
2006;94:1194–203. 
Au
t o
r P
r
f
Volume 33, Number 2, 2014 11
Relationship between Genotoxic effects of bReast canceR tReatments and patient basal dna inteGRity
33. Lou JL, Chen ZJ, Wei J, He JL, Jin LF, Chen SJ, Zheng W, 
Xu SJ. Response of lymphocytes to radiation in untreated 
breast cancer patients as detected with three different 
genetic assays. Biomed Environ Sci. 2008;21:499–508.
34. Møller P, Knudsen LE, Loft S, Wallin H. The comet assay 
as a rapid test in biomonitoring occupational exposure to 
DNA-damaging agents and effect of confounding factors. 
Cancer Epidemiol Biomarkers Prev. 2000;9:1005–15. 
35. Kopjar N, Zeljezić D, Garaj-Vrhovac V. Evaluation of 
DNA damage in white blood cells of healthy human 
volunteers using the alkaline comet assay and the chromo-
some aberration test, Acta Biochim Pol. 2006;53:321–36.
36. Shahidi M, Mozdarani H, Bryant PE. Radiation sensitivity 
of leukocytes from healthy individuals and breast cancer 
patients as measured by the alkaline and neutral comet 
assay. Cancer Lett. 2007;257:263–73.
37. Rajeswari N, Ahuja YR, Malini U, Chandrashekar S, 
Balakrishna N, Rao KV, Khar A. Risk assessment in 
first degree female relatives of breast cancer patients 
using the alkaline Comet assay. Carcinogenesis. 2000;21: 
557–61.
38. Collins A, Dušinská M, Franklin M, Somorovská M, 
Petrovská H, Duthie S, Fillion L, Panayiotidis M, Rašlová 
K, Vaughan N. Comet assay in human biomonitoring 
studies: reliability, validation, and applications. Environ 
Mol Mutagen. 1997;30:139–46. 
39. Dusinska M, Collins AR. The comet assay in human bio-
monitoring: gene-environment interactions. Mutagenesis. 
2008;23:191–205. 
40. Møller P, Friis G, Christensen PH, Risom L, Plesner 
G, Kjaersgaard J, Vinzents P, Jensen A, Tved M. Intra-
laboratory comet assay sample scoring exercise for 
determination of formamidopyrimidine DNA glycosylase 
sites in human mononuclear blood cell DNA. Free Radic 
Res. 2004;38:1207–14. 
41. Forchhammer L, Bräuner EV, Folkmann JK, Danielsen 
PH, Nielsen C, Jensen A, Loft S, Friis G, Møller P. 
Variation in assessment of oxidatively damaged DNA in 
mononuclear blood cells by the comet assay with visual 
scoring. Mutagenesis. 2008;23:223–31. 
42. Duez P, Dehon G, Dubois J. Validation of raw data mea-
surements in the comet assay. Talanta. 2004;63:879–86. 
43. Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann 
A, Kobayashi H, Miyamae Y, Rojas E, Ryu JC, Sasaki 
YF. Single cell gel/comet assay: guidelines for in vitro 
and in vivo genetic toxicology testing. Environ Mol 
Mutagen. 2000;35:206–21. 
44. Hartmann A, Plappert U, Poetter F, Suter W. Comparative 
study with the alkaline comet assay and the chromosome 
aberration test. Mutat Res. 2003;536:27–38. 
45. Dhawan A, Bajpayee M, Parmar D. Comet assay: a reli-
able tool for the assessment of DNA damage in different 
models. Cell Biol Toxicol. 2009;25:5–32.
Au
tho
r P
of
